多剂量口服5-单硝酸异山梨酯缓释片及普通片的药代动力学和生物利用度研究

对10名健康男性受试者连续6d多剂量交叉poIS-5-MN缓释片和普通片的药代动力学性质和相对生物利用度进行了研究。结果表明:IS-5-MN缓释片和普通片的T_max分别为5.0h和1.4h(P<0.05),前者的缓释效果十分明显;AUC经对数转换后的多种统计分析表明,IS-5-MN缓释片(40mg)与IS-5-MN普通片(20mg×2)生物等效;IS-5-MN缓释片的相对生物利用度为108.95%;IS-5-MN缓释片和普通片的C_min分别为74.20ng·ml^-1和134.42ng·ml^-1(P<0.05),而两种制剂的其他药代动力学参数如C_max,AUC²⁴₀,AUC^∞₀,Ke,T_1/2以及波动系数(FI)等均无显著性差异(P<0.05)。多次给药后两种制剂都无明显的蓄积。

Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers]

The pharmacokinetics of a new sustained release tablets (40 mg, qd) of isosorbide-5-mononitrate (IS-5-MN) was investigated together with a conventional preparation (20 mg, bid) after multiple oral administration in ten healthy human subjects using an open, randomized two-way crossover experimental design. Based on three statistical analyses of the area under the plasma concentration-time curve (AUC), the two tablet formulations are judged to be bioequivalent (P > 0.1), with a relative bioavailability of 108.95% for the IS-5-MN sustained release formulation. Pharmacokinetic data showed that the sustained release formulation reached mean peak plasma levels significantly later and lower minimum plasma concentration (Cmin), compared with the conventional preparation. But no statistically significant difference was found for other pharmacokinetic parameters including peak plasma levels (Cmax), AUC, elimination constant (Ke), elimination half-life (T1/2) and fluctuation index (FI) between the two preparations (P > 0.05).